Comparison

Pirmitegravir European Partner

Item no. HY-130000-10mg
Manufacturer MedChem Express
CASRN 2245231-10-9
Amount 10 mg
Quantity options 100 mg 10 mg 1 ea 25 mg 50 mg 5 mg
Specific against other
Citations [1]Maehigashi T, et al. A highly potent and safe pyrrolopyridine-based allosteric HIV-1 integrase inhibitor targeting host LEDGF/p75-integrase interaction site. PLoS Pathog. 2021;17(7):e1009671.
Smiles O=C([C@H](C1=C(N=C(C2=C1C3=CC=C(C=C3)Cl)N(C(C)=C2C)CC4=CN(N=C4)C)C)OC(C)(C)C)O
Alias STP0404
Available
Product Description
Pirmitegravir is a potent and first-in-class inhibitor of allosteric integrase (ALLINI) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC50 in human PBMCs with a >24, 000 therapeutic index against HIV-1. Pirmitegravir harbors outstanding anti-virus and safety properties[1].
Shipping
Room temperature
Manufacturers Applications
COVID-19-anti-virus
MolecularWeight
495.01
Clinical Information
Phase 2
Manufacturers Research Area
Infection
Solubility
10 mM in DMSO
Target
HIV; HIV Integrase
Manufacturers Target
HIV; HIV Integrase
Manufacturers Pathway
Anti-infection; Metabolic Enzyme/Protease
Manufacturers Product type
Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close